Type Congenic; Targeted Mutation; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Additional information on Congenic nomenclature. Species laboratory mouse Donating Investigator Dr. Malcolm J Low, University of Michigan Medical School Description
Mice homozygous for this targeted mutation (D4R-/-) are viable and fertile. With exon 2 of the mutant locus deleted, the truncated transcript is predicted to produce a 131 amino acid mutant polypeptide. Homozygous mice may exhibit locomotor supersensitivity to ethanol, cocaine, and methamphetamine, as well as alterations in dopamine synthesis and function, glutamate levels and metabolism, behavioral responses to novelty, and spontaneous locomotor activity in both novel and familiar environments. These D4R-mutant mice may be useful in studying dopamine/neurotransmitter function, drug addiction, Parkinson's disease, and schizophrenia or other psychoses.In an attempt to offer alleles on well-characterized or multiple genetic backgrounds, alleles are frequently moved to a genetic background different from that on which an allele was first characterized. It should be noted that the phenotype could vary from that originally described. We will modify the strain description if necessary as published results become available.
Development
A targeting vector was designed to replace exon 2 of the targeted gene with a neomycin resistance cassette. The construct was electroporated into 129P2/OlaHsd-derived E14TG2A embryonic stem (ES) cells. Correctly targeted ES cells were injected into recipient blastocysts, and chimeric males were bred to C57BL/6J females. Heterozygous D4R-mutant mice were bred to wildtype siblings or C57BL/6J mice for approximately 30 generations (including to C57BL/6J for 5 most recent generations) prior to arrival at The Jackson Laboratory. Upon arrival, mice were bred to C57BL/6J for at least one generation to establish the colony.
| Control | ||
|---|---|---|
| 000664 C57BL/6J | ||
| Considerations for Choosing Controls | ||
Parkinson's Disease Models
005987 129-Achetm1Loc/J 007587 129S-Park2tm1Rpa/J 002779 129S-Parp1tm1Zqw/J 017001 129S.B6N-Plk2tm1Elan/J 016198 129S6.Cg-Tg(Camk2a-tTA)1Mmay/JlwsJ 004608 B6(Cg)-Htra2mnd2/J 008133 B6.129-Sncbtm1Sud/J 004744 B6.129P2-Esr1tm1Ksk/J 013586 B6.129P2-Gt(ROSA)26Sortm1Nik/J 002609 B6.129P2-Nos2tm1Lau/J 008843 B6.129P2-Sncgtm1Vlb/J 016566 B6.129S-Hcn1tm2Kndl/J 004322 B6.129S1-Mapk10tm1Flv/J 003190 B6.129S2-Drd2tm1Low/J 006582 B6.129S4-Park2tm1Shn/J 017946 B6.129S4-Pink1tm1Shn/J 005934 B6.129S4-Ucp2tm1Lowl/J 004936 B6.129S6(Cg)-Spp1tm1Blh/J 012453 B6.129X1(FVB)-Lrrk2tm1.1Cai/J 017009 B6.129X1-Nfe2l2tm1Ywk/J 009346 B6.Cg-Lrrk2tm1.1Shn/J 005491 B6.Cg-Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J 006577 B6.Cg-Park7tm1Shn/J 000567 B6.Cg-T2J +/+ Qkqk-v/J 007004 B6.Cg-Tg(Camk2a-tTA)1Mmay/DboJ 003139 B6.Cg-Tg(DBHn-lacZ)8Rpk/J 007673 B6.Cg-Tg(Gad1-EGFP)3Gfng/J 012466 B6.Cg-Tg(Lrrk2)6Yue/J 012467 B6.Cg-Tg(Lrrk2*G2019S)2Yue/J 008323 B6.Cg-Tg(Mc4r-MAPT/Sapphire)21Rck/J 008321 B6.Cg-Tg(Npy-MAPT/Sapphire)1Rck/J 008324 B6.Cg-Tg(Pmch-MAPT/CFP)1Rck/J 008322 B6.Cg-Tg(Pomc-MAPT/Topaz)1Rck/J 007894 B6.Cg-Tg(Rgs4-EGFP)4Lvt/J 012588 B6.Cg-Tg(TH-ALPP)1Erav/J 012265 B6.Cg-Tg(THY1-SNCA*A30P)TS2Sud/J 008859 B6.Cg-Tg(THY1-SNCA*A53T)F53Sud/J 008135 B6.Cg-Tg(THY1-SNCA*A53T)M53Sud/J 008601 B6.Cg-Tg(Th-cre)1Tmd/J 013583 B6.Cg-Tg(tetO-LRRK2)C7874Cai/J 000544 B6.D2-Cacna1atg/J 012445 B6.FVB-Tg(LRRK2)WT1Mjfa/J 012446 B6.FVB-Tg(LRRK2*G2019S)1Mjfa/J 006660 B6.SJL-Slc6a3tm1.1(cre)Bkmn/J 008364 B6;129-Chattm1(cre/ERT)Nat/J 009688 B6;129-Dbhtm2(Th)Rpa Thtm1Rpa/J 008883 B6;129-Gt(ROSA)26Sortm1(SNCA*A53T)Djmo/TmdJ 008889 B6;129-Gt(ROSA)26Sortm2(SNCA*119)Djmo/TmdJ 008886 B6;129-Gt(ROSA)26Sortm3(SNCA*E46K)Djmo/TmdJ 009347 B6;129-Lrrk2tm1.1Shn/J 016209 B6;129-Lrrk2tm2.1Shn/J 016210 B6;129-Lrrk2tm3.1Shn/J 013050 B6;129-Pink1tm1Aub/J 004807 B6;129-Psen1tm1Mpm Tg(APPSwe,tauP301L)1Lfa/Mmjax 006390 B6;129-Sncatm1Sud Sncbtm1.1Sud/J 008532 B6;129-Thtm1(cre/Esr1)Nat/J 008333 B6;129P2-Dldtm1Ptl/J 008333 B6;129P2-Dldtm1Ptl/J 002596 B6;129P2-Nos2tm1Lau/J 003243 B6;129S-Tnfrsf1atm1Imx Tnfrsf1btm1Imx/J 003692 B6;129X1-Sncatm1Rosl/J 016575 B6;C3-Tg(PDGFB-LRRK2*G2019S)340Djmo/J 016576 B6;C3-Tg(PDGFB-LRRK2*R1441C)574Djmo/J 008169 B6;C3-Tg(Prnp-MAPT*P301S)PS19Vle/J 004479 B6;C3-Tg(Prnp-SNCA*A53T)83Vle/J 000231 B6;C3Fe a/a-Csf1op/J 012450 B6;D2-Tg(tetO-SNCA)1Cai/J 013725 B6;SJL-Tg(LRRK2)66Mjff/J 016555 B6;SJL-Tg(Nqo1-ALPP)1Jaj/J 008473 B6;SJL-Tg(THY1-SNCA*A30P)M30Sud/J 008134 B6;SJL-Tg(THY1-SNCA*A30P)TS2Sud/J 016976 B6C3-Tg(tetO-SNCA*A53T)33Vle/J 000506 B6C3Fe a/a-Qkqk-v/J 003741 B6D2-Tg(Prnp-MAPT)43Vle/J 018768 B6N.Cg-Tg(SNCA*E46K)3Elan/J 012621 C.129S(B6)-Chrna3tm1.1Hwrt/J 016120 C57BL/6-Lrrk1tm1.1Mjff/J 012444 C57BL/6-Lrrk2tm1Mjfa/J 008389 C57BL/6-Tg(THY1-SNCA)1Sud/J 012769 C57BL/6-Tg(Thy1-Sncg)HvP36Putt/J 005706 C57BL/6-Tg(tetO-CDK5R1/GFP)337Lht/J 006618 C57BL/6-Tg(tetO-COX8A/EYFP)1Ksn/J 008245 C57BL/6J-Tg(Th-SNCA)5Eric/J 008239 C57BL/6J-Tg(Th-SNCA*A30P*A53T)39Eric/J 016122 C57BL/6N-Lrrk1tm1.1Mjff Lrrk2tm1.1Mjff/J 016121 C57BL/6N-Lrrk2tm1.1Mjff/J 016123 C57BL/6N-Sncatm1Mjff/J 016936 C57BL/6N-Tg(Thy1-SNCA)12Mjff/J 017682 C57BL/6N-Tg(Thy1-SNCA)15Mjff/J 007677 CB6-Tg(Gad1-EGFP)G42Zjh/J 009610 FVB/N-Tg(LRRK2)1Cjli/J 009609 FVB/N-Tg(LRRK2*G2019S)1Cjli/J 009604 FVB/N-Tg(LRRK2*R1441G)135Cjli/J 009090 FVB/NJ-Tg(Slc6a3-PARK2*Q311X)AXwy/J 017678 FVB;129-Pink1tm1Aub Tg(Prnp-SNCA*A53T)AAub/J 017744 FVB;129-Tg(Prnp-SNCA*A53T)AAub/J 010710 FVB;129S6-Sncatm1Nbm Tg(SNCA)1Nbm/J 010788 FVB;129S6-Sncatm1Nbm Tg(SNCA*A30P)1Nbm Tg(SNCA*A30P)2Nbm/J 010799 FVB;129S6-Sncatm1Nbm Tg(SNCA*A53T)1Nbm Tg(SNCA*A53T)2Nbm/J 004808 STOCK Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J 000942 STOCK Pitx3ak/2J 014092 STOCK Tg(ACTB-tTA2,-MAPT/lacZ)1Luo/J 006340 STOCK Tg(Gad1-EGFP)98Agmo/J 017000 STOCK Tg(SNCA*E46K)3Elan/J 008474 STOCK Tg(THY1-SNCA*A53T)F53Sud/J 008132 STOCK Tg(THY1-Snca)M1mSud/J 012441 STOCK Tg(tetO-LRRK2*G2019S)E3Cai/J 012442 STOCK Tg(tetO-SNCA*A53T)E2Cai/J 012449 STOCK Tg(teto-LRRK2)C7874Cai/J View Parkinson's Disease Models (109 strains)
Visit the Parkinson's Disease Resource site for helpful information on Parkinson's and research resources.
View Related Disease (OMIM) Terms
Related Disease (OMIM) Terms provided by MGI
- Potential model based on gene homology relationships. Phenotypic similarity to the human disease has not been tested. Attention Deficit-Hyperactivity Disorder; ADHD (DRD4)
Novelty Seeking Personality Trait (DRD4)
View Mammalian Phenotype Terms
Mammalian Phenotype Terms provided by MGI
assigned by genotype
The following phenotype information may relate to a genetic background differing from this JAX® Mice strain.
Drd4tm1Dkg/Drd4tm1Dkg
involves: 129P2/OlaHsd * C57BL/6J
- behavior/neurological phenotype
- *normal* behavior/neurological phenotype
- amphetamine-treated mice exhibit normal reductions in prepulse inhibition and startle reactivity (MGI Ref ID J:55027)
- decreased exploration in new environment
- in the open field test, homozygotes make fewer entries into the center, but do not differ in overall levels of activity relative to wild-type mice (MGI Ref ID J:76023)
- in the emergence test, homozygotes spend more time in the cylinder and make fewer entries into the cylinder relative to wild-type mice (MGI Ref ID J:76023)
- in the novel object test, homozygotes exhibit a smaller increase in % of time spent in the center after introduction of the cup relative to wild-type mice (MGI Ref ID J:76023)
- overall, homozygotes display the largest reductions in behavioral responses to novelty in the test that maximizes approach behaviors (novel object test), and the smallest reductions in the test that maximizes avoidance behavior (open field test) (MGI Ref ID J:76023)
- decreased vertical activity
- homozygotes exhibit fewer rearing episodes in an open field environment relative to wild-type mice (MGI Ref ID J:43061)
- enhanced behavioral response to cocaine
- homozygotes display a dose-dependent hypersensitivity to the locomotor-stimulating effects of cocaine and methamphetamine (MGI Ref ID J:43061)
- enhanced coordination
- homozygotes outperform their wild-type littermates on the rotarod, with 50% fewer falls and a 2.5-fold increase in the length of time remaining on the rotarod (MGI Ref ID J:43061)
- hyperactivity elicited by ethanol administration
- homozygotes are supersensitive to the locomotor-stimulating effects of ethanol (20% v/v) relative wild-type mice (MGI Ref ID J:43061)
- hypoactivity
- impaired behavioral response to addictive substance
- unlike wild-type, catecholamine-depleted, akinetic-rendered homozygotes fail to exhibit a 40% suppression of apomorphine-induced locomotor activity in response to 0.6 mg/kg clozapine (MGI Ref ID J:43061)
- however, both genotypes of mice exhibit complete loss of apomorphine-induced locomotion in response to 6 mg/kg clozapine however, both genotypes of mice exhibit completely loss of apomorphine-induced locomotion in response to 6 mg/kg clozapine (MGI Ref ID J:43061)
- nervous system phenotype
- *normal* nervous system phenotype
- amphetamine-treated mice exhibit normal reductions in prepulse inhibition and startle reactivity (MGI Ref ID J:55027)
- increased dopamine level
- following DOPA decarboxylase inhibition, homozygotes accumulate more L-DOPA in the dorsal striatum-caudate putamen (CPU) relative to wild-type mice (MGI Ref ID J:43061)
- homozygotes exhibit elevated dopamine synthesis and its conversion to DOPAC in the dorsal striatum, as shown by a 93% increase of DOPAC content in CPU and a 1.9-fold increase in DOPAC/DA ratio relative to wild-type mice (MGI Ref ID J:43061)
- homeostasis/metabolism phenotype
- increased dopamine level
- following DOPA decarboxylase inhibition, homozygotes accumulate more L-DOPA in the dorsal striatum-caudate putamen (CPU) relative to wild-type mice (MGI Ref ID J:43061)
- homozygotes exhibit elevated dopamine synthesis and its conversion to DOPAC in the dorsal striatum, as shown by a 93% increase of DOPAC content in CPU and a 1.9-fold increase in DOPAC/DA ratio relative to wild-type mice (MGI Ref ID J:43061)
Drd4tm1Dkg/Drd4tm1Dkg
involves: 129P2/OlaHsd
- vision/eye phenotype
- abnormal eye electrophysiology
- abnormal vision
- optokinetic tracking indicates a decrease in contrast sensitivity over multiple spatial frequencies (MGI Ref ID J:185955)
- behavior/neurological phenotype
- abnormal circadian rhythm
- on day 2 in constant darkness, circadian regulation of the light-adapted electroretinographic response is abolished (MGI Ref ID J:185955)
View Research Applications
Research Applications
This mouse can be used to support research in many areas including:
Neurobiology Research
Behavioral and Learning Defects
genes regulating preferences to alcohol
Parkinson's Disease
Receptor Defects
dopamine receptor
| Allele Symbol | Drd4tm1Dkg | ||
|---|---|---|---|
| Allele Name | targeted mutation 1, David K Grandy | ||
| Allele Type | Targeted (knock-out) | ||
| Common Name(s) | D4-; D4KO; D4R -; Drd4-; | ||
| Mutation Made By | David Grandy, Oregon Heath Sciences University | ||
| Strain of Origin | 129P2/OlaHsd | ||
| ES Cell Line Name | E14TG2a | ||
| ES Cell Line Strain | 129P2/OlaHsd | ||
| Gene Symbol and Name | Drd4, dopamine receptor D4 | ||
| Chromosome | 7 | ||
| Gene Common Name(s) | AW125663; D4DR; D4R; D4RA; Drd-4; expressed sequence AW125663; | ||
| Molecular Note | A neomycin resistance cassette replaced exon 2. RT-PCR analysis demonstrated that a mutated transcript was produced from this allele that spliced exon 1 to exon 3. This mutation causes a shift in the reading frame that is predicted to result in the production of a truncated protein. [MGI Ref ID J:43061] | ||
Genotyping Protocols
Drd4tm1Dkg, Standard PCR
Helpful Links
Genotyping resources and troubleshooting
Helms CM; Gubner NR; Wilhelm CJ; Mitchell SH; Grandy DK. 2008. D(4) receptor deficiency in mice has limited effects on impulsivity and novelty seeking. Pharmacol Biochem Behav 90(3):387-93. [PubMed: 18456309] [MGI Ref ID J:136871]
Kruzich PJ; Suchland KL; Grandy DK. 2004. Dopamine D4 receptor-deficient mice, congenic on the C57BL/6J background, are hypersensitive to amphetamine. Synapse 53(2):131-9. [PubMed: 15170825] [MGI Ref ID J:136873]
Rubinstein M; Phillips TJ; Bunzow JR; Falzone TL; Dziewczapolski G ; Zhang G ; Fang Y ; Larson JL ; McDougall JA ; Chester JA ; Saez C ; Pugsley TA ; Gershanik O ; Low MJ ; Grandy DK. 1997. Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and methamphetamine. Cell 90(6):991-1001. [PubMed: 9323127] [MGI Ref ID J:43061]
Thomas TC; Grandy DK; Gerhardt GA; Glaser PE. 2008. Decreased Dopamine D4 Receptor Expression Increases Extracellular Glutamate and Alters Its Regulation in Mouse Striatum. Neuropsychopharmacology :. [PubMed: 18536704] [MGI Ref ID J:136870]
Thomas TC; Kruzich PJ; Joyce BM; Gash CR; Suchland K; Surgener SP; Rutherford EC; Grandy DK; Gerhardt GA; Glaser PE. 2007. Dopamine D4 receptor knockout mice exhibit neurochemical changes consistent with decreased dopamine release. J Neurosci Methods 166(2):306-14. [PubMed: 17449106] [MGI Ref ID J:136872]
Drd4tm1Dkg relatedBek MJ; Wang X; Asico LD; Jones JE; Zheng S; Li X; Eisner GM; Grandy DK; Carey RM; Soares-da-Silva P; Jose PA. 2006. Angiotensin-II type 1 receptor-mediated hypertension in D4 dopamine receptor-deficient mice. Hypertension 47(2):288-95. [PubMed: 16380537] [MGI Ref ID J:135774]
Cepeda C; Hurst RS; Altemus KL; Flores-Hernandez J; Calvert CR; Jokel ES; Grandy DK; Low MJ; Rubinstein M; Ariano MA; Levine MS. 2001. Facilitated glutamatergic transmission in the striatum of D2 dopamine receptor-deficient mice. J Neurophysiol 85(2):659-70. [PubMed: 11160501] [MGI Ref ID J:103965]
Dulawa SC; Grandy DK; Low MJ; Paulus MP; Geyer MA. 1999. Dopamine D4 receptor-knock-out mice exhibit reduced exploration of novel stimuli. J Neurosci 19(21):9550-6. [PubMed: 10531457] [MGI Ref ID J:76023]
Falzone TL; Gelman DM; Young JI; Grandy DK; Low MJ; Rubinstein M. 2002. Absence of dopamine D4 receptors results in enhanced reactivity to unconditioned, but not conditioned, fear. Eur J Neurosci 15(1):158-64. [PubMed: 11860516] [MGI Ref ID J:89406]
Fan X; Xu M; Hess EJ. 2010. D2 dopamine receptor subtype-mediated hyperactivity and amphetamine responses in a model of ADHD. Neurobiol Dis 37(1):228-36. [PubMed: 19840852] [MGI Ref ID J:156905]
Gan L; Falzone TL; Zhang K; Rubinstein M; Baldessarini RJ; Tarazi FI. 2004. Enhanced expression of dopamine D(1) and glutamate NMDA receptors in dopamine D(4) receptor knockout mice. J Mol Neurosci 22(3):167-78. [PubMed: 14997010] [MGI Ref ID J:121245]
Grady DL; Thanos PK; Corrada MM; Barnett JC Jr; Ciobanu V; Shustarovich D; Napoli A; Moyzis AG; Grandy D; Rubinstein M; Wang GJ; Kawas CH; Chen C; Dong Q; Wang E; Volkow ND; Moyzis RK. 2013. DRD4 genotype predicts longevity in mouse and human. J Neurosci 33(1):286-91. [PubMed: 23283341] [MGI Ref ID J:193918]
Herrmann R; Heflin SJ; Hammond T; Lee B; Wang J; Gainetdinov RR; Caron MG; Eggers ED; Frishman LJ; McCall MA; Arshavsky VY. 2011. Rod vision is controlled by dopamine-dependent sensitization of rod bipolar cells by GABA. Neuron 72(1):101-10. [PubMed: 21982372] [MGI Ref ID J:178532]
Jackson CR; Chaurasia SS; Hwang CK; Iuvone PM. 2011. Dopamine D receptor activation controls circadian timing of the adenylyl cyclase 1/cyclic AMP signaling system in mouse retina. Eur J Neurosci 34(1):57-64. [PubMed: 21676039] [MGI Ref ID J:177942]
Jackson CR; Chaurasia SS; Zhou H; Haque R; Storm DR; Iuvone PM. 2009. Essential roles of dopamine D4 receptors and the type 1 adenylyl cyclase in photic control of cyclic AMP in photoreceptor cells. J Neurochem 109(1):148-57. [PubMed: 19166506] [MGI Ref ID J:149171]
Jackson CR; Ruan GX; Aseem F; Abey J; Gamble K; Stanwood G; Palmiter RD; Iuvone PM; McMahon DG. 2012. Retinal Dopamine Mediates Multiple Dimensions of Light-Adapted Vision. J Neurosci 32(27):9359-9368. [PubMed: 22764243] [MGI Ref ID J:185955]
Katz JL; Chausmer AL; Elmer GI; Rubinstein M; Low MJ; Grandy DK. 2003. Cocaine-induced locomotor activity and cocaine discrimination in dopamine D4 receptor mutant mice. Psychopharmacology (Berl) 170(1):108-14. [PubMed: 12783155] [MGI Ref ID J:103880]
Kvajo M; McKellar H; Gogos JA. 2012. Avoiding mouse traps in schizophrenia genetics: lessons and promises from current and emerging mouse models. Neuroscience 211:136-64. [PubMed: 21821099] [MGI Ref ID J:184660]
Kwon OB; Paredes D; Gonzalez CM; Neddens J; Hernandez L; Vullhorst D; Buonanno A. 2008. Neuregulin-1 regulates LTP at CA1 hippocampal synapses through activation of dopamine D4 receptors. Proc Natl Acad Sci U S A 105(40):15587-92. [PubMed: 18832154] [MGI Ref ID J:143450]
Maison SF; Liu XP; Eatock RA; Sibley DR; Grandy DK; Liberman MC. 2012. Dopaminergic Signaling in the Cochlea: Receptor Expression Patterns and Deletion Phenotypes. J Neurosci 32(1):344-355. [PubMed: 22219295] [MGI Ref ID J:179360]
Michaelides M; Pascau J; Gispert JD; Delis F; Grandy DK; Wang GJ; Desco M; Rubinstein M; Volkow ND; Thanos PK. 2010. Dopamine D4 receptors modulate brain metabolic activity in the prefrontal cortex and cerebellum at rest and in response to methylphenidate. Eur J Neurosci 32(4):668-76. [PubMed: 20646063] [MGI Ref ID J:171781]
Nir I; Harrison JM; Haque R; Low MJ; Grandy DK; Rubinstein M; Iuvone PM. 2002. Dysfunctional light-evoked regulation of cAMP in photoreceptors and abnormal retinal adaptation in mice lacking dopamine D4 receptors. J Neurosci 22(6):2063-73. [PubMed: 11896146] [MGI Ref ID J:75589]
Ogilvie JM; Hakenewerth AM; Gardner RR; Martak JG; Maggio VM. 2009. Dopamine receptor loss of function is not protective of rd1 rod photoreceptors in vivo. Mol Vis 15:2868-78. [PubMed: 20038975] [MGI Ref ID J:157088]
Pozdeyev N; Tosini G; Li L; Ali F; Rozov S; Lee RH; Iuvone PM. 2008. Dopamine modulates diurnal and circadian rhythms of protein phosphorylation in photoreceptor cells of mouse retina. Eur J Neurosci 27(10):2691-700. [PubMed: 18547251] [MGI Ref ID J:137182]
Ralph RJ; Varty GB; Kelly MA; Wang YM; Caron MG; Rubinstein M ; Grandy DK ; Low MJ ; Geyer MA. 1999. The dopamine D2, but not D3 or D4, receptor subtype is essential for the disruption of prepulse inhibition produced by amphetamine in mice. J Neurosci 19(11):4627-33. [PubMed: 10341260] [MGI Ref ID J:55027]
Rubinstein M; Cepeda C; Hurst RS; Flores-Hernandez J; Ariano MA; Falzone TL; Kozell LB; Meshul CK; Bunzow JR; Low MJ; Levine MS; Grandy DK. 2001. Dopamine D4 receptor-deficient mice display cortical hyperexcitability. J Neurosci 21(11):3756-63. [PubMed: 11356863] [MGI Ref ID J:69457]
Seeman P; Weinshenker D; Quirion R; Srivastava LK; Bhardwaj SK; Grandy DK; Premont RT; Sotnikova TD; Boksa P; El-Ghundi M; O'dowd BF; George SR; Perreault ML; Mannisto PT; Robinson S; Palmiter RD; Tallerico T. 2005. Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. Proc Natl Acad Sci U S A 102(9):3513-8. [PubMed: 15716360] [MGI Ref ID J:96985]
Thanos PK; Habibi R; Michaelides M; Patel UB; Suchland K; Anderson BJ; Robinson JK; Wang GJ; Grandy DK; Volkow ND. 2010. Dopamine D4 receptor (D4R) deletion in mice does not affect operant responding for food or cocaine. Behav Brain Res 207(2):508-11. [PubMed: 19853629] [MGI Ref ID J:156902]
Wang HD; Stanwood GD; Grandy DK; Deutch AY. 2009. Dystrophic dendrites in prefrontal cortical pyramidal cells of dopamine D1 and D2 but not D4 receptor knockout mice. Brain Res 1300:58-64. [PubMed: 19747903] [MGI Ref ID J:157411]
Yuen EY; Zhong P; Yan Z. 2010. Homeostatic regulation of glutamatergic transmission by dopamine D4 receptors. Proc Natl Acad Sci U S A 107(51):22308-13. [PubMed: 21135234] [MGI Ref ID J:167300]
Animal Health Reports
Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200.Colony Maintenance
Breeding & Husbandry When maintaining a live colony, homozygous mice may be bred together.
| Pricing for USA, Canada and Mexico shipping destinations |
|
Cryopreserved Mice - Ready for Recovery
Animals Provided
Price (US dollars $) Cryorecovery* $1980.00 At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.
Standard Supply
Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.
Supply Notes
- Cryorecovery - Standard.
Progeny testing is not required.
The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 11 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.Cryorecovery to establish a Dedicated Supply for greater quantities of mice.
Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).
| Pricing for International shipping destinations |
|
Cryopreserved Mice - Ready for Recovery
Animals Provided
Price (US dollars $) Cryorecovery* $2574.00 At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.
Standard Supply
Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.
Supply Notes
- Cryorecovery - Standard.
Progeny testing is not required.
The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 11 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.Cryorecovery to establish a Dedicated Supply for greater quantities of mice.
Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).
|
|
Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.
| Control | ||
|---|---|---|
| 000664 C57BL/6J | ||
| Considerations for Choosing Controls | ||
| Control Pricing Information for Genetically Engineered Mutant Strains. | ||
For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.
In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.
Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.